Clinical trial data from completed trials are now beginning to be shared through a variety of channels. While skeptics remain, evidence is growing that this data can lead to practice-changing behavior in patient care.
Dave Handelsman
Advertisement
Articles by Dave Handelsman
Dave Handelsman offers a smart approach to dealing with the EMA's new guidelines on the anonymization of clinical trial data.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Vinay Prasad Out at CBER for Second Time in Under a Year
2
Novo Nordisk Signs Deal with Hims & Hers
3
Ipsen Withdraws Tazverik from Market Due to Emerging Data from Clinical Trial
4
Mergers and Acquisitions Roundup: GSK and Alfasigma Enter Licensing Agreement for Linerixibat, Servier Enters $2.5 Billion Definitive Agreement to Acquire Day One Pharmaceuticals
5